Baotainingtang Biotechnology

Baotainingtang Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of next-generation immune cell therapies for oncology. The company's core focus is on Chimeric Antigen Receptor T-cell (CAR-T) therapies specifically engineered to target and eliminate solid tumors, addressing a major unmet need in cancer treatment. Its lead therapeutic candidates include programs targeting Glypican-3 (GPC3) for the treatment of hepatocellular carcinoma and Mesothelin for various epithelial-derived solid tumors. Baotainingtang utilizes a proprietary cell engineering platform to improve the infiltration and persistence of T-cells within the complex tumor microenvironment. The company is currently advancing its pipeline through early-phase clinical trials in collaboration with leading medical institutions in China.